APTOSE BIOSCIENCES INC (APTO) Stock News

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AML

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial ...

Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket

Shares of Rumble Inc.

Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Aptose Announces Positive Decision by Nasdaq Hearings Panel

Aptose Announces Positive Decision by Nasdaq Hearings Panel

Aptose Announces Positive Decision by Nasdaq Hearings Panel ...

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML...

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML...

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials

Aptose's AML drug tuspetinib selected for NCI's prestigious clinical research program for ability to target broad spectrum of AML and MDS populations ...

Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering

Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering

Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering ...

Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering

Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering

Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering ...

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy ...

Aptose Reports Results for the Third Quarter 2024

Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML

Aptose Reports Results for the Third Quarter 2024

Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML...

Aptose Announces Results from Special Meeting of Shareholders

Aptose Announces Results from Special Meeting of Shareholders

Aptose Announces Results from Special Meeting of Shareholders ...

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patients

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib...

Aptose Announces Adjournment of its Special Meeting of Shareholders

Aptose Announces Adjournment of its Special Meeting of Shareholders

Aptose Announces Adjournment of its Special Meeting of Shareholders...

APTO Stock Earnings: Aptose Biosciences Beats EPS for Q2 2024

APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the second quarter of 2024.

APTO Stock Earnings: Aptose Biosciences Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aptose Biosciences (NASDAQ:APTO) just reported results for the second quarter o...

Aptose Reports Results for the Second Quarter 2024

Aptose Reports Results for the Second Quarter 2024

Aptose Reports Results for the Second Quarter 2024...

Aptose Announces Receipt of Deficiency Notice from Nasdaq

Aptose Announces Receipt of Deficiency Notice from Nasdaq

SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage...

Aptose Announces Results from Annual and Special Meeting of Shareholders

Aptose Announces Results from Annual and Special Meeting of Shareholders...